Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03816358
Title Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

pancreatic adenocarcinoma

Therapies

Anetumab ravtansine + Gemcitabine + Nivolumab

Anetumab ravtansine + Nivolumab

Anetumab ravtansine + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.